Ribupatide injection (KAI-9531) An investigational once-weekly injectable GLP-1/GIP receptor dual agonist being studied for obesity in global Phase 3 trials.
Visit productCosigns Received
Be the first Cosign
Put your name behind Ribupatide injection (KAI-9531).
Add it to your Products I use list and share why you use it.